


# An mCRPC patient fails AR-targeted therapy. What's next?

Determining the next treatment decision for mCRPC patients who have failed an androgen receptor (AR)-targeted therapy can be challenging



## mCRPC diagnosis

### Patient information

- Age: 56
- Stage: metastatic castration-resistant prostate cancer (mCRPC)
- PSA level post AR-targeted therapy: 64 ng/mL
- PSA level post chemotherapy: 8 ng/mL
- ECOG performance status: 1

### Physician information

- Physician specialty: hematology/oncology
- Physician practice: Cancer Treatment Centers of America

## AR-targeted therapy failure



### Treatment(s) administered:

- Enzalutamide for ≈ 8 months
- Docetaxel for 6 cycles

### AR-targeted therapy failure indicated by:

- Rapidly rising PSA levels during the course of 8 months
- Scans indicated new involved pelvic lymph nodes

## Next treatment



### Reason(s) for Oncotype DX AR-V7 Nucleus Detect® testing

- Patient exhibited failure on enzalutamide and was placed on chemotherapy
- After patient was stable on chemotherapy, physician wanted to assess if patient could be placed on a less toxic therapy based on patient's nuclear AR-V7 status

Learn how the AR-V7 Nucleus Detect® assay helped guide this patient's next treatment

oncotypeDX®  
AR-V7 Nucleus Detect  
powered by Epic Sciences

ECOG = Eastern Cooperative Oncology Group; PSA = prostate-specific antigen.

ONCOTYPE DX AR-V7 NUCLEUS DETECT® ASSAY

# Direct more mCRPC patients toward the right course of treatment

Oncotype DX AR-V7 Nucleus Detect assay can help guide your treatment decisions



Nuclear AR-V7  
**Negative**

**Test results**

- Result: AR-V7-
- **This means that AR-V7 protein was NOT detected in the nucleus of any circulating tumor cells (CTCs).** This patient may have clinical response to and benefit from a different AR-targeted therapy, regardless of prior lines of therapy<sup>1-3</sup>

**Post-test decision and outcomes**

**Physician action:** Test results made it easy to discuss options with patient. Physician confidently chose to place patient on abiraterone and prednisone.

**Patient reaction:** Relieved to find out that he had other options and did not need to continue chemotherapy.

**Patient response to treatment:**

- Patient tolerating switch from chemotherapy to abiraterone well
- PSA levels have been stable for over 2 months

**Available and covered by Medicare**

**ORDER NOW for your mCRPC patients**

Contact your local Genomic Health representative or Customer Service at 866 ONCOTYPE (866-662-6897).

**References:** 1. Scher et al. *JAMA Oncol.* 2016. 2. Scher et al. *JAMA Oncol.* 2018. 3. Armstrong et al. *J Clin Oncol.* 2018. AR-V7 Nucleus Detect, Genomic Health, Making cancer care smarter, Oncotype DX, Oncotype DX AR-V7 Nucleus Detect, and Oncotype IQ are trademarks of Genomic Health, Inc. All other trademarks are the properties of their respective owners. © 2019 Genomic Health, Inc. All rights reserved. GHI60057\_0919



**oncotypeDX®**  
*AR-V7 Nucleus Detect*  
powered by Epic Sciences